八大胜:Corporate Overview
八大胜:Development History
八大胜:Corporate Culture
八大胜:About Founder
八大胜:Core Team
八大胜:R&D Platform
八大胜:Process Development
八大胜:Press Releases
八大胜:Talent Concept
Richard Liqun Wang: China's Cell and Gene Therapy Poised to Take the Lead
八大胜:2024-09-09
Dr. Richard Liqun Wang, Founder, Chairman, and CEO of Neukio Biotherapeutics, presented the current state, trends, bottlenecks, and prospects of Cell and Gene Therapy (CGT) research and development in China.
八大胜:See More
Richard Wang: A Seventeen-Year Odyssey of an Overseas PhD Returnee in the Pursuit of Domestic Innovative Drug Development
八大胜:2024-02-23
Entrepreneur's insight: Innovation poses a formidable challenge that requires significant dedication and hard work. The complexities involved in this endeavor are often underestimated. To become a successful entrepreneur, it is crucial to have a clear goa
Neukio Biotherapeutics completed Series A-1 financing, to accelerate discovery and development of next generation cell therapy products
八大胜:2022-09-02
The funds raised will play important roles in accelerating the preclinical and clinical validation of induced pluripotent stem cell (iPSC)-derived off-the-shelf CAR-NK cell therapy products, and supporting team recruitment and expansion.
Neukio Biotherapeutics has completed $40m Angel round of financing and is committed to developing new NK technology platform and products
Press Releases
2021-10-25
Neukio Biotherapeutics, a newly established company, recently announced the completion of its $40m Angel round of financing led by Lilly Asia Venture (LAV), with the participation of IDG Capital and Sherpa Investments. The fund will be used mainly for th
See More
Richard Wang: Perks enjoyed by companies based in the FTZ
2023-09-29
Wang Liqun, founder, chairman, and CEO of Neukio Biotherapeutics
Neukio Biotherapeutics Reached Strategic Collaboration with Tofflon Science and Technology Group Co. Ltd to Expedite Large-scale Production of Next Generation Allogenic Cell Therapies
八大胜:2023-03-21
EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell Therapies
八大胜:2022-02-09
(February 9, 2022) EdiGene, Inc. and Neukio Biotherapeutics today announced an R&D collaboration to develop next-generation immune cell therapies.
八大胜:2021-10-25
<tr id='RKBtC'><strong id='1BlS5'></strong><small id='bVHgl'></small><button id='tufWu'></button><li id='NT52u'><noscript id='y7bun'><big id='0IhKl'></big><dt id='1agDI'></dt></noscript></li></tr><ol id='R6cCz'><option id='kQ2AY'><table id='HpTvy'><blockquote id='8PJ9e'><tbody id='4A1F6'></tbody></blockquote></table></option></ol><u id='CN76u'></u><kbd id='soMoM'><kbd id='RRCCj'></kbd></kbd>
-442.jpg)